Mayo Clinic
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 12, 2024), Mayo Clinic reported 4 stock positions worth $3.0 million. Its top holding was iShares MSCI Acwi ETF (ACWI) at 64.4% of the portfolio, followed by Zentalis Pharmaceuticals (ZNTL, 25.3%) and Unity Biotechnology (UNBX, 5.5%). Compared with Q1 2024, it sold out of 1. The biggest sale was an exit from Perspective Therapeutics (CATX).
- Most Recent 13F
- Q3 2024
- Location
- Rochester, MN
- CIK
- 0001318153
- Portfolio Value
- $3.0M (Q2 2024)
- SEC Filing
- 0000950123-24-007732 ↗ filed Aug 12, 2024
Holdings Value
Holdings 4 stocks · $3.0M
| ACWI iShares MSCI Acwi ETF | 64.41% | 17,359 | $2.0M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 25.27% | 187,143 | $765K | No change |
| UNBX Unity Biotechnology Inc. | 5.53% | 124,081 | $168K | No change |
| NEUROONE MED TECHNOLOGIES CO | 4.80% | 181,754 | $145K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −14.03 |
Portfolio Buys Q1 2024 → Q2 2024
| None this quarter. | |||